By using the Oncomine and Tumor Immune Estimation Resource (TIMER) databases, PrognoScan, GEPIA and Kaplan-Meier plotter databases, ACE-2 over-expression was found to be associated with higher overall survival in uterine corpus endometrial carcinoma (Hazard Ratio = 0.47; 95%CI: 0.30–0.73; Logrank p = 0.0007), kidney renal papillary cell carcinoma (Hazard Ratio = 0.44; 95%CI: 0.24–0.81; Logrank p = 0.0063), lung adenocarcinoma (Hazard Ratio = 0.60; 95%CI: 0.44–0.82; Logrank p = 0.0011) and liver hepatocellular carcinoma (Hazard Ratio = 0.55; 95%CI: 0.38–0.80; Logrank p = 0.0017) [42]. The gene discussed is ACE2; the disease is neoplasm.